NCT00202917View on ClinicalTrials.gov

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

December 31, 2010

Conditions
Hematologic Malignancies
Interventions
DRUG

Fludarabine

DRUG

Thiotepa

DRUG

Melphalan

DRUG

OKT-3

PROCEDURE

CD3/CD19 depletion on CliniMACS

Trial Locations (7)

20246

Medical Center University of Hamburg, Hamburg

45122

Center for Marrow Transplantation, Essen

48129

Medical Center University of Muenster, Münster

65191

Deutsche Klinik für Diagnostik, Wiesbaden

72076

South West German Cancer Center, University of Tuebingen Medical Center, Tübingen

D-01307

University of Dresden Medical Center, Dresden

D-97070

University of Wuerzburg Medical Center, Würzburg

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT00202917 - Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter